Cardiac Biotech Solutions Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2018	FY 2017
Period Ending	Dec '18 Dec 31, 2018	Mar '18 Mar 31, 2018	Mar '17 Mar 31, 2017
Revenue	0.05	0.04	0.03
Revenue Growth	-	11.11%	-
Cost of Revenue	0.02	0.01	0.02
Gross Profit	0.03	0.02	0.02
Selling, General & Admin	0.46	0.49	0.37
Other Operating Expenses	0.66	0.66	0.02
Operating Expenses	0.78	1.15	0.39
Operating Income	-0.75	-1.13	-0.37
Other Non Operating Income (Expenses)	0.11	-	-0.02
Pretax Income	-0.64	-1.13	-0.39
Net Income	-0.64	-1.13	-0.39
Net Income to Common	-0.64	-1.13	-0.39
Net Income Growth	-	-	-
Shares Outstanding (Basic)	59	58	57
Shares Outstanding (Diluted)	59	58	57
Shares Change	-	1.52%	-
EPS (Basic)	-0.01	-0.02	-0.01
EPS (Diluted)	-0.01	-0.02	-0.01
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2018	FY 2017
Period Ending	Dec '18 Dec 31, 2018	Mar '18 Mar 31, 2018	Mar '17 Mar 31, 2017
Free Cash Flow	-	-0.77	-0.06
Free Cash Flow Per Share	-	-0.01	-0.00
Gross Margin	54.34%	64.15%	49.32%
Operating Margin	-1486.00%	-3090.31%	-1122.17%
Profit Margin	-1271.68%	-3090.31%	-1171.49%
Free Cash Flow Margin	-	-2109.05%	-191.28%
EBITDA	-	-1.13	-0.37
D&A For EBITDA	-	0	0
EBIT	-0.75	-1.13	-0.37